SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
|☐||Preliminary Proxy Statement|
|☐||Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))|
|☐||Definitive Proxy Statement|
|☒||Definitive Additional Materials|
|☐||Soliciting Material under §240.14a-12|
MAGENTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|☒||No fee required.|
|☐||Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.|
Title of each class of securities to which transaction applies:
Aggregate number of securities to which transaction applies:
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
Proposed maximum aggregate value of transaction:
Total fee paid:
|☐||Fee paid previously with preliminary materials.|
|☐||Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.|
Amount Previously Paid:
Form, Schedule or Registration Statement No.:
TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903
Magenta Therapeutics, Inc.
Important Notice Regarding the
Availability of Proxy Materials
For The Stockholder Meeting to be held on
June 1, 2021
|For Stockholders of record on April 5, 2021|
|This communication presents only an overview of the more complete proxy|
materials, which contain important information and are available to you on
the Internet or by mail. This is not a ballot. You cannot use this notice to
vote your shares. We encourage you to access and review all of the
important information contained in the proxy materials before voting.
|To view the proxy materials, and to obtain directions to attend the meeting,|
go to: www.proxydocs.com/MGTA
|To vote your proxy while visiting this site, you will need the 12 digit control|
number in the box below.
Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.
Proxy Materials Available to View or Receive: 1. Annual Report 2. Proxy Statement
If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this years annual meeting, you must make this request on or before May 21, 2021.
To order paper materials, use one of the following methods.
When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.
* If requesting materials by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting materials.
Magenta Therapeutics, Inc.
Annual Meeting of Stockholders
THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
FOR THE ELECTION OF THE DIRECTOR NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSAL 2
To elect four class III directors to our Board of Directors, to serve until the 2024 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.
1.01 Bruce Booth, D.Phil.
1.02 Thomas O. Daniel, M.D.
1.03 Jason Gardner, D.Phil.
1.04 Alison F. Lawton
To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
Note: In their discretion, the Named Proxies are authorized to vote upon any other matters that are properly brought by or at the discretion of the Board of Directors before the Annual Meeting and at any adjournments or postponements thereof.